Remedy Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development and commercialization of CIRARA, a treatment for acute central nervous system conditions where there are inadequate or no approved existing therapies, this week announced the appointment of Richard Steinhart as chief financial officer.
“I am very excited about joining the company and partnering with (CEO) Sven (Jacobson) and the entire Remedy team,” Steinhart said. “I am pleased to have the opportunity to assist in the process of bringing the life-saving drug CIRARA to market as well as building sustainable value for all of our stakeholders.”
Steinhart has nearly 30 years of experience in the biotechnology and medical device industries in roles including venture capital investor, board member, operating executive and investment banker. He was most recently employed by MELA Sciences Inc. as the company’s senior vice president of finance.
He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant.
"We are extremely pleased to welcome Rich to the Remedy executive team," Jacobson said. “This is an exciting stage in our company's history and his strong health care background and track record helping organizations grow their businesses makes him ideal for our organization."
Alerts Sign-up